Hadassah

Clinical Trial Begins at Hadassah University Medical Center with New Drug to Treat Stroke

Monday, Oct 24 2011

Clinical Trial Begins at Hadassah University Medical Center with New Drug To Treat Stroke. A Phase IIa clinical trial with a medicine to treat ischemic stroke has begun at the Hadassah University Medical Center, based on the research of Prof. Abd Al-Roof Higazi, head of the Department of Clinical Biochemistry at Hadassah Hospital Ein-Kerem.

The safety and clinical effectiveness of THR-18, a product of Thrombotech, will be tested on patients with ischemic stroke in seven medical centers throughout Europe, India, and Israel. Thrombotech Technologies Ltd. is a Portfolio Company of Clal Biotechnology Industries Ltd., Israel's largest active life sciences investment company, and Hadasit Bio-Holdings Ltd., a publicly traded subsidiary of Hadasit, Hadassah's technology transfer company, with biotech products all based on intellectual property developed and owned by the Hadassah University Medical Center.

Approximately 25 patients will be divided into three groups. One group will receive the currently used medication for treating ischemic stroke--tPA--and the other two groups will be treated with THR-18, in two different doses, in combination with tPA. Plans are for an evaluation of the trial to be completed within a year.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More